Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
medical source : Www.hancockjaffe.com save search
New Topline Efficacy Data from the enVVeno Medical VenoValve® Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
Published: 2024-04-16 (Crawled : 15:00) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: -1.22%
H: 0.0%
C: -2.06%
venovalve symposium topline medical trial
enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
Published: 2024-04-09 (Crawled : 13:00) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: 0.58%
H: 3.07%
C: -2.88%
commercial medical
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
Published: 2024-03-21 (Crawled : 17:00) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: 0.17%
H: 4.63%
C: 3.83%
medical
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
Published: 2024-03-15 (Crawled : 13:30) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: 0.0%
H: 5.47%
C: 4.94%
medical
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve® Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
Published: 2024-03-06 (Crawled : 14:30) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: 2.96%
H: 3.48%
C: -9.7%
enous2024 venovalve positive topline meeting trial today
enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Published: 2024-02-29 (Crawled : 22:00) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: 4.17%
H: 0.46%
C: -0.31%
update medical financial results
enVVeno Medical Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-07-31 (Crawled : 22:00) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: 2.24%
H: 2.98%
C: 2.98%
update medical financial results
enVVeno Medical to Host Virtual KOL Event on July 18, 2023
Published: 2023-07-14 (Crawled : 12:20) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: 0.0%
H: 2.75%
C: -3.36%
medical
enVVeno Medical Provides Enrollment Update for Ongoing VenoValve® U.S. Pivotal Study and Announces Upcoming Investor and KOL Events
Published: 2023-07-05 (Crawled : 13:00) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: -0.36%
H: 8.42%
C: 5.94%
venovalve update ongoing medical study
enVVeno Medical Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
Published: 2023-03-02 (Crawled : 23:00) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: -0.29%
H: 1.03%
C: -1.89%
medical financial update results
enVVeno Medical to Present at Cowen’s 43rd Annual Health Care Conference
Published: 2023-02-08 (Crawled : 15:00) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: -1.94%
H: 2.97%
C: 2.81%
COWN | $38.99 0.31% 0.0% 0
|
Finance
|
| O: -0.08%
H: 0.18%
C: 0.18%
care conference health medical
enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer
Published: 2023-01-18 (Crawled : 14:00) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: -0.41%
H: 2.56%
C: 1.17%
medical technology
Positive 3-Year VenoValve® First-in-Human Data Presented at 49th Annual VEITH Symposium on Vascular and Endovascular Issues
Published: 2022-11-17 (Crawled : 18:00) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: -0.0%
H: 0.91%
C: 0.0%
venovalve symposium positive
enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study
Published: 2022-11-07 (Crawled : 15:00) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: 0.67%
H: 1.84%
C: -0.92%
fda venovalve review study
enVVeno Medical Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-10-27 (Crawled : 23:00) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: 0.89%
H: 1.52%
C: 0.4%
financial update results
enVVeno Medical to Present at the Ladenburg Thalmann 2022 Healthcare Conference
Published: 2022-09-22 (Crawled : 12:20) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: 0.0%
H: 3.93%
C: -6.62%
conference
enVVeno Medical Announces the Development of a Transcatheter Based Replacement Venous Valve for the Treatment of Chronic Venous Insufficiency
Published: 2022-09-21 (Crawled : 21:00) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: 0.0%
H: 3.93%
C: -6.62%
treatment
enVVeno Medical to Host Conference Call and Webcast on September 21, 2022
Published: 2022-09-19 (Crawled : 13:00) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: 1.32%
H: 0.65%
C: -2.99%
conference
enVVeno Medical to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Published: 2022-09-12 (Crawled : 12:20) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: 3.41%
H: 3.43%
C: 3.03%
global conference
enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations
Published: 2022-08-16 (Crawled : 12:20) - hancockjaffe.com
NVNO | $4.82 0.84% 16K
|
Manufacturing
|
| O: 5.32%
H: 0.0%
C: -5.54%
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
ZCMD | $1.86 28.28% 29M
|
Commercial Services
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.3022 24.82% 51M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.